AllSci News
BMS Q2'26: Milvexian slips as admilparant becomes the key catalyst
Bristol-Myers Squibb (NYSE: BMY) held its Q2 2026 earnings call on July 30, 2026, with two headline pipeline changes: the Factor XIa inhibitor milvexian...
AbbVie Q2'26: Etentamig nears regulatory test while Temab-A broadens oncology ambitions
AbbVie Inc. (NYSE: ABBV) held its Q2 2026 earnings call on July 31, 2026, during which the most consequential pipeline disclosures centered on three areas:...
Sanofi Q2'26: Pipeline review claims amlitelimab as Garijo tightens R&D discipline
Sanofi's Q2 2026 earnings call, held on August 3, 2026, was defined less by commercial performance than by a wave of pipeline decisions — including the...
AstraZeneca, Bristol Myers Squibb explored potential merger, Financial Times reports
AstraZeneca and Bristol Myers Squibb (NYSE: BMY) held preliminary merger discussions that could create one of the largest pharmaceutical companies ever...
CREATE Medicines licenses Monash's targeted LNP chemistry to expand in vivo CAR platform
Cambridge, Massachusetts-based CREATE Medicines, Inc. has entered a strategic research collaboration and exclusive license agreement with Australia-based...
Pharmanovia takes on Impact's senaparib outside US, China for EUR 423.5m
China-based Impact Therapeutics (HKEX: 07630.HK) has signed an exclusive license agreement with UK-based Pharmanovia, granting the specialty pharma company...
Novo's ziltivekimab misses cardiovascular endpoint despite biomarker success
Novo Nordisk's ZEUS trial has delivered a clean failure for ziltivekimab, the company's anti-IL-6 monoclonal antibody, dealing a setback to the hypothesis...
CREATE clears Australian ethics review for first-in-human in vivo CAR-T study
Cambridge, Massachusetts-based CREATE Medicines, Inc. has received Human Research Ethics Committee (HREC) approval in Australia to begin a first-in-human...
Scancell taps Nasdaq reverse merger to fund Phase III melanoma program
UK-based Scancell Holdings plc (AIM: SCLP) has announced an all-share merger agreement with Burlington, Massachusetts-based Neuphoria Therapeutics Inc....
J&J secures option to acquire Sail in USD 3.5 billion in vivo CAR-T alliance
Cambridge, Massachusetts-based Sail Biomedicines and Johnson & Johnson (NYSE: JNJ) announced a strategic collaboration to develop a portfolio of in vivo...
Intero Biosystems's intestinal organoid platform backed by SBIR
Aurora, Colorado-based Intero Biosystems Inc. has received a USD 1.05 million Small Business Innovation Research (SBIR) Phase II grant from the National...
Hengrui wins China approval for first domestically developed basal insulin analog
China's National Medical Products Administration (NMPA) has approved insulin sudelidec injection — marketed by Jiangsu Hengrui Pharmaceuticals (HKEX: 01276)...
Insilico launches AI benchmarking platform for drug discovery models
Insilico Medicine Opens Its AI Drug Discovery Benchmark to Outside Scrutiny
Replimune overcomes skeptical FDA briefing as panel backs RP1 in 10-3 vote
With an FDA decision just two days away, Woburn, Massachusetts-based Replimune Group (Nasdaq: REPL) received a broadly favorable signal from an advisory...
Insilico's AI-designed TEAD inhibitor secures FDA fast track for mesothelioma
Cambridge, Massachusetts-based Insilico Medicine (HKEX: 3696) announced receipt of US FDA Fast Track Designation (FTD) for ISM6331, a small-molecule...
The AllSci Brief
Free, systematic R&D and deal news. Daily.